BTEC:SW:SW-iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) USD (USD)

ETF | Others |

Last Closing

USD 5.504

Change

-0.32 (-5.46)%

Market Cap

N/A

Volume

0.03M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-07 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
CHDIV:SW UBS ETF (CH) - MSCI Switzerlan..

+0.22 (+1.72%)

USD 1,244,681.59B
SPISI:SW UBS ETF (CH) - SPI® ESG (CHF)..

+0.18 (+1.16%)

USD 590,186.66B
SWICHA:SW UBS ETF (CH) – MSCI Switzerl..

+0.26 (+1.32%)

USD 226,274.25B
SWUSAH:SW UBS ETF (CH) – MSCI Switzerl..

+0.40 (+1.51%)

USD 226,274.21B
SWEUAH:SW UBS ETF (CH) – MSCI Switzerl..

N/A

USD 226,274.20B
RGLDS:SW Raiffeisen ETF Solid Gold A US..

+32.00 (+0.33%)

USD 134,034.93B
RGLDSH:SW Raiffeisen ETF Solid Gold H CH..

-12.00 (-0.19%)

USD 134,034.91B
RGLDOH:SW Raiffeisen ETF Solid Gold Ounc..

+13.40 (+0.68%)

USD 134,034.86B
RGLDO:SW Raiffeisen ETF Solid Gold Ounc..

+20.50 (+0.82%)

USD 134,034.85B
SPICHA:SW UBS ETF (CH) – SPI® (CHF) A..

+0.70 (+0.95%)

USD 131,872.43B

ETFs Containing BTEC:SW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -11.74% 30% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.74% 30% F 31% F
Trailing 12 Months  
Capital Gain -11.23% 17% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.23% 16% F 21% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 5.20% 49% F 51% F
Dividend Return 5.20% 48% F 50% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 7.97% 55% F 60% D-
Risk Adjusted Return 65.32% 42% F 48% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.